Related Experiment Videos
Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression
P J Barnes1, R Boutilier, D Chiasson
1Department of Pathology, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia B3H 2Y9, Canada.
Breast Cancer Research and Treatment
|May 4, 2005
Summary
Metaplastic breast carcinomas (MBC) are rare, aggressive breast cancers with diverse pathology. This study highlights their poor disease-free survival, emphasizing the need for further research into their unique clinical behavior and carcinogenesis.
Area of Science:
- Oncology
- Pathology
- Breast Cancer Research
Background:
- Metaplastic breast carcinomas (MBC) are rare malignant tumors characterized by a mix of carcinomatous and non-epithelial elements.
- MBC subtypes include sarcomatoid, carcinosarcoma, adenosquamous, and pure squamous cell carcinomas.
- Limited data exists on the pathological features and clinical outcomes of MBC.
Purpose of the Study:
- To review the pathological characteristics of metaplastic breast carcinomas.
- To analyze the clinical outcomes of patients diagnosed with MBC.
- To investigate the incidence and recognition of MBC over time.
Main Methods:
- Retrospective review of 26 MBC cases diagnosed between 1971 and 2000.
- Immunohistochemistry for ER/PR and HER2/neu.
- Clinical outcome data collected from medical records and physician contact.
Main Results:
- All 26 MBCs were high-grade with a median size of 3.7 cm.
- 4 out of 13 cases with lymph node dissection showed metastases.
- Disease-free survival was 53% at a median follow-up of 23 months.
- HER2/neu overexpression was rare, seen in only one case.
Conclusions:
- MBC exhibits pathological heterogeneity and distinct clinical behavior compared to typical breast cancers.
- An increasing number of MBC diagnoses suggest improved recognition.
- Poor disease-free survival necessitates further research for optimal clinical management.